Oral Isotretinoin and Its Uses in Dermatology: A Review.

Anon Paichitrojjana, Anand Paichitrojjana

Journal: Drug design, development and therapy 2023;17():2573-2591

PMID: 37649956

Abstract

In 1982, the Food and Drug Administration (FDA) of the United States of America approved isotretinoin (13-cis-retinoic acid), a retinoid derivative of vitamin A, to treat severe recalcitrant acne vulgaris. Apart from its prescribed use for severe acne, evidence suggests that isotretinoin is commonly used off-label to treat mild-to-moderate acne, inflammatory skin conditions, genodermatoses, skin cancer, and other skin disorders. This is due to its anti-inflammatory, immunomodulatory, and antineoplastic properties. Some "off-label" use is successful, while others are ineffective. Therefore, this information is essential to clinicians for deciding on the appropriate use of isotretinoin. In this article, we aim to review the most updated evidence-based data about the use of oral isotretinoin in dermatology.

© 2023 Paichitrojjana and Paichitrojjana.

Address: School of Anti-Aging and Regenerative Medicine, Mae Fah Luang University, Bangkok, Thailand.; Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.